Phase 4 Psoriasis Trial, Recruiting NCT05004727 Sponsor: NYU Langone Health Condition: Psoriasis
Back to Psoriasis

Phase 4 Psoriasis Trial, Recruiting

NCT05004727
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You can be male or female
  • You have been diagnosed with psoriasis by a skin doctor (dermatologist) for at least 2 years (this applies to at least 30% of participants in the trial)
  • You are willing and able to give your consent to take part
  • You meet the "high-risk psoriasis" criteria, meaning you have had psoriasis for more than 2 years, it covers more than 3% of your body surface area, and a special ultrasound scan of your joints and tendons has shown certain findings above a specific threshold (confirm with trial site)

Who may not be able to join:

  • You currently have joint pain due to inflammation, pain where tendons attach to bones (enthesitis), or swelling of a whole finger or toe (dactylitis), found during a physical examination
  • You are currently taking certain medications that suppress the immune system (such as methotrexate or apremilast), or you have ever taken a biologic therapy (a type of medicine made from living cells)
  • Your blood tests show certain markers associated with rheumatoid arthritis at medium or high levels (confirm with trial site)
  • You currently have an active cancer
  • You have a history of a painful condition affecting many joints, such as osteoarthritis, rheumatoid arthritis, gout, or similar joint conditions that could make it hard to tell if psoriatic arthritis is developing
  • You have a condition that would make it unsafe to take the study drug (guselkumab), including a serious active infection or untreated latent (inactive) tuberculosis
  • You have a known allergy or sensitivity to the study drug

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Jose Scher, MD, NYU Langone Health

Phone: 6465017400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
16 February 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

Change in Musculoskeletal, Power Doppler Ultrasound (MSK-PDUS) Composite Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov